Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
19
2023 to 2026
Breakthrough
3
Accelerated
3
Priority review
10
Orphan
13
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 6 | 2 |
| 2024 | 2 | 1 |
| 2025 | 1 | 1 |
| 2026 | 3 | 3 |
19 approvals
Newest first. Hover a badge for what it means.
- Klygefa (Gefurulimab) · Alexion PharmNov 13, 2026Original approval · BLA 761488NovelOrphan
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
- Juvmo (Tavapadon) · AbbvieSep 25, 2026
To treat Parkinson's disease in adults
- Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
- Tauklarify (Florquinitau F-18) · Cerveau LantheusAug 13, 2026
To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology
- Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
To treat narcolepsy type 1
- Avlayah (Tividenofusp Alfa-Eknm) · Denali Therapeutics Inc.Mar 24, 2026Original approval · BLA 761485NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
- Subvenite (Lamotrigine) · Owp PharmsSep 16, 2025Original approval · NDA 218879Approval letter
- Imaavy (Nipocalimab-Aahu) · Janssen BiotechApr 29, 2025
To treat generalized myasthenia gravis
- Kisunla (Donanemab-Azbt) · Eli Lilly COJul 2, 2024
To treat Alzheimer's disease
- Vigafyde (Vigabatrin) · Pyros PharmsJun 17, 2024
- Duvyzat (Givinostat Hydrochloride) · Italfarmaco SpaMar 21, 2024
To treat Duchenne muscular dystrophy in individuals aged 6 years and older
- Wainua (Autoinjector) (Eplontersen Sodium) · Astrazeneca AbDec 21, 2023
To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
- Agamree (Vamorolone) · Catalyst PharmsOct 26, 2023
To treat Duchenne muscular dystrophy
- Zilbrysq (Zilucoplan Sodium) · Ucb INCOct 17, 2023
To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive
- Rystiggo (Rozanolixizumab-Noli) · Ucb INCJun 26, 2023
To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positive
- Qalsody (Tofersen) · Biogen MaApr 25, 2023
To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation
- Zavzpret (Zavegepant Hydrochloride) · PfizerMar 9, 2023
To treat migraine
- Skyclarys (Omaveloxolone) · Biogen USFeb 28, 2023
To treat Friedrich's ataxia
- Leqembi (Lecanemab-Irmb) · Eisai INCJan 6, 2023Original approval · BLA 761269NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat Alzheimer's disease
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.